Browse KMT2C

Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF05965 F/Y rich C-terminus
PF05964 F/Y-rich N-terminus
PF00628 PHD-finger
PF00856 SET domain
Function

Histone methyltransferase. Methylates 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Central component of the MLL2/3 complex, a coactivator complex of nuclear receptors, involved in transcriptional coactivation. KMT2C/MLL3 may be a catalytic subunit of this complex. May be involved in leukemogenesis and developmental disorder.

> Gene Ontology
 
Biological Process GO:0006479 protein methylation
GO:0008213 protein alkylation
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0032259 methylation
GO:0034968 histone lysine methylation
GO:0043414 macromolecule methylation
GO:0051568 histone H3-K4 methylation
Molecular Function GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0016746 transferase activity, transferring acyl groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0042054 histone methyltransferase activity
GO:0042800 histone methyltransferase activity (H3-K4 specific)
Cellular Component GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0044666 MLL3/4 complex
> KEGG and Reactome Pathway
 
KEGG hsa00310 Lysine degradation
Reactome R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-1266738: Developmental Biology
R-HSA-3214841: PKMTs methylate histone lysines
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KMT2C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KMT2C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.08; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KMT2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0540.822
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2820.791
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3010.712
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0220.941
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2960.924
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4250.915
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2450.533
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2580.888
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2650.895
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2390.822
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1360.435
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0650.13
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KMT2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.512.36.20.518
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.515.33.20.757
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117195.913.10.355
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.19.1140.596
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91666.731.235.50.115
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 596033.326.70.58
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 477528.646.40.242
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.53.76.80.393
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KMT2C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KMT2C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KMT2C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KMT2C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KMT2C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KMT2C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKMT2C
Namelysine (K)-specific methyltransferase 2C
Aliases KIAA1506; HALR; MLL3; myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein; histone-lysine N-methy ......
Chromosomal Location7q36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KMT2C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.